Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 2
2003 1
2004 1
2005 2
2006 4
2007 4
2008 6
2009 8
2010 16
2011 17
2012 16
2013 10
2014 15
2015 12
2016 9
2017 6
2018 3
2019 5
2020 2
2021 2
2022 3
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 24812245

124 results

Results by year

Filters applied: . Clear all
Page 1
(18)F-fluorodeoxyglucose positron emission tomography versus computed tomography in predicting histopathological response to epidermal growth factor receptor-tyrosine kinase inhibitor treatment in resectable non-small cell lung cancer.
van Gool MH, Aukema TS, Schaake EE, Rijna H, Codrington HE, Valdés Olmos RA, Teertstra HJ, van Pel R, Burgers SA, van Tinteren H, Klomp HM. van Gool MH, et al. Ann Surg Oncol. 2014 Sep;21(9):2831-7. doi: 10.1245/s10434-014-3791-6. Epub 2014 May 21. Ann Surg Oncol. 2014. PMID: 24845729 Clinical Trial.
Quantitative analysis of response to treatment with erlotinib in advanced non-small cell lung cancer using 18F-FDG and 3'-deoxy-3'-18F-fluorothymidine PET.
Kahraman D, Scheffler M, Zander T, Nogova L, Lammertsma AA, Boellaard R, Neumaier B, Ullrich RT, Holstein A, Dietlein M, Wolf J, Kobe C. Kahraman D, et al. J Nucl Med. 2011 Dec;52(12):1871-7. doi: 10.2967/jnumed.111.094458. Epub 2011 Nov 7. J Nucl Med. 2011. PMID: 22065872 Free article. Clinical Trial.
Changes in 18F-fluorodeoxyglucose and 18F-fluorodeoxythymidine positron emission tomography imaging in patients with non-small cell lung cancer treated with erlotinib.
Mileshkin L, Hicks RJ, Hughes BG, Mitchell PL, Charu V, Gitlitz BJ, Macfarlane D, Solomon B, Amler LC, Yu W, Pirzkall A, Fine BM. Mileshkin L, et al. Clin Cancer Res. 2011 May 15;17(10):3304-15. doi: 10.1158/1078-0432.CCR-10-2763. Epub 2011 Mar 1. Clin Cancer Res. 2011. PMID: 21364032 Clinical Trial.
A phase II study of ¹⁸F-fluorodeoxyglucose PET-CT in non-small cell lung cancer patients receiving erlotinib (Tarceva); objective and symptomatic responses at 6 and 12 weeks.
O'Brien ME, Myerson JS, Coward JI, Puglisi M, Trani L, Wotherspoon A, Sharma B, Cook G, Ashley S, Gunapala R, Chua S, Popat S. O'Brien ME, et al. Eur J Cancer. 2012 Jan;48(1):68-74. doi: 10.1016/j.ejca.2011.10.033. Epub 2011 Nov 24. Eur J Cancer. 2012. PMID: 22119198 Clinical Trial.
124 results